Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960282 · ClinicalTrials.gov registry record
Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
A clinical trial, sponsored by University of Southern California.
- Terminated
- Registry status
- 21
- Enrollment target
NCT02960282: Clinical Trial study, sponsored by University of Southern California.
NCT02960282 is a clinical trial that was terminated before completion, run by University of Southern California. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02960282 was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- 21 participants
- Enrollment target
Study Summary
This research trial studies the gut microbiome in fecal samples from patients with cancer that has spread to other parts of the body who are undergoing chemotherapy or immunotherapy. Studying samples of feces from patients with metastatic cancer in the laboratory may help doctors learn if the make-up of the gut microbiome has a positive or negative influence to a patient's response to chemotherapy or immunotherapy.
Primary Outcome
The presence and amounts of species and their protocols will be compared to tumor response.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-10-20 |
| Est. Completion | 2022-04-13 |
Why NCT02960282 stopped before completion
NCT02960282 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT02960282 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02960282 about?
NCT02960282 is a clinical study titled "Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy". This research trial studies the gut microbiome in fecal samples from patients with cancer that has spread to other parts of the body who are undergoing chemotherapy or immunotherapy. Studying samples of feces from patients with metastatic cancer in the laboratory may help doctors learn if the make-u...
What is the current status of trial NCT02960282?
This trial is currently terminated. The enrollment target is 21 participants. The study started on 2016-10-20. Estimated completion is 2022-04-13.
What interventions are being tested in trial NCT02960282?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02960282?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI